STOCKHOLM, March 25, 2010 /PRNewswire/ -- Clanotech AB, a Karolinska Development portfolio company, today announced the appointment of Bo Oberg as new member of the board. Bo Oberg has 40 years experience in drug development and is cofounder of the listed company Medivir AB.
"We are happy to have Bo Oberg in the Clanotech Board of Directors and I look forward to him being actively involved and contributing to the development of the company," says Patrizia Caldirola, CEO of Clanotech AB.
Conny Bogentoft, CEO of Karolinska Development added "His vast experience in drug development will be of great value for the company as it enter into later development phases His experience will help the development of Clanotech which will strengthen the Karolinska Development portfolio."
Bo Oberg, PhD, Adj Prof, is currently CEO of Medivir HIV Franchise AB. He was a cofounder of Medivir AB in 1988, and has held a number of executive and board positions in that company including Chairman of the Board from 1992 to 1996. He was Senior Director of Antiviral Therapy R&D at Astra from 1978 to 1988 and has over 40 years experience in leading positions within drug development. Former positions include corporate board positions at Clean Chemical Sweden AB, BioAgri AB, Agrivir AB and Accuro Immunology AB. He has, and continues to serve, on a number of scientific advisory committees; he is Chair of the Advisory Board of the RAPID Centre and Member of the Advisory Board of the Centre for Infectious Medicine. He was Member of the Board of the Swedish Research Council for Medicine, Director of the Board of the International Society for Antiviral Research and Member of the Committee on Biotechnology of the Swedish Board for Technical Development, Member of WHO Advisory Group on Antiviral Chemotherapy and is a Member of the Royal Society of Sciences in Uppsala.
To The Editors
Clanotech is a privately-held company that discovers and develops pharmaceuticals to treat cancer and age related macular degeneration by targeting biological pathways associated with angiogenesis. Clanotech is part of the Karolinska Development portfolio. For more information, please visit http://www.clanotech.se
About Karolinska Development
Karolinska Development manages one of the largest portfolios of life science companies in Europe.
Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio also includes a total of 19 potential first in class products.
CONTACT: For further information, please contact: Patrizia Caldirola, CEO,
Clanotech AB, Phone +46(0)703747179, E-mail: